For US Healthcare Professionals

I am a:

For US Healthcare Professionals

Full Prescribing Information

The TREMFYA® 8-week dosing schedule was optimized in clinical trials1,2

One 100-mg injection
on day 1

Then 1 injection
4 weeks later

Then 1 injection
every 8 weeks thereafter

Available in 2 dosage forms

Prefilled syringe (NDC: 57894-640-01)

One-Press patient-controlled injector (NDC: 57894-640-11)

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training. In active PsA, TREMFYA® may be administered alone or in combination with a conventional DMARD (eg, methotrexate).

*Frequency of maintenance injections for TREMFYA® after the first year.

DMARD=disease-modifying antirheumatic drug.

References: 1. TREMFYA® (guselkumab) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Lebwohl M, Langley RG, Zhu Y, et al. Use of dose-exposure-response relationships in Phase 2 and Phase 3 guselkumab studies to optimize dose selection in psoriasis. J Eur Acad Dermatol Venereol. 2019;33(11):2082-2086.

One-Press patient-controlled injector

TREMFYA® is the first and only anti–IL-23 with a patient-controlled, self-injection device; the patient controls the rate of delivery

Not actual size.

Device features designed with patients in mind

  • Can be used in physician's office or at home after physician approval and proper training
  • Needle guard keeps needle out of view
  • Soft “click” indicates when the injection is complete
  • Not made with natural rubber latex

Please see the full Instructions for Use (IFU) for TREMFYA® One-Press patient-controlled injector.

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.

Injection demonstration videos

Watch these easy-to-follow injection demonstration videos for TREMFYA®.

The injection demonstration videos are not meant to replace the IFU that are supplied with TREMFYA®. Instruct patients to read the IFU before using their TREMFYA® prefilled syringe or One-Press injector and each time they get a refill.

Download instructions for use

TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.